Amgen has shared positive results from a late-stage study of its immunotherapy Imdelltra (tarlatamab-dlle) in small cell lung cancer (SCLC). The global DeLLphi-304 trial has been comparing the drug ...

Point.1 Synthesis: smarter omni-channel planning to avoid wastage And lastly, we have Point.1 Synthesis, a product to aid brand experience activation. Synthesis uses Point.1 data touchpoint usage, ...